Corporate deck outlines immunology strategy and pipeline
Kymera outlined a strategy to commercialize oral targeted protein degraders in immunology, aiming to match biologics-like activity with pill convenience.
Lead asset KT-621, an oral STAT6 degrader, is positioned for dupilumab-like efficacy across Type 2 inflammatory diseases; Phase 2b atopic dermatitis data are due by year-end 2026.
Phase 3 atopic dermatitis trials are planned to start by mid-2027; Phase 2b asthma readout is targeted for late 2027.
Second wholly owned program KT-579, an IRF5 degrader, targets lupus and related autoimmune diseases; Phase 1 healthy-volunteer data are expected in 4Q26.
Partnered pipeline includes KT-485, an IRAK4 degrader with an IND targeted for 2027, alongside KT-200, a CDK2 degrader for solid tumors.
KYMR•
